Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Recruiting
Phase 2Interventional Study
Malignant Melanoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Male
Trial phase
Phase 2
Study type
Interventional
Purpose
Diagnostic
Participants needed
16 (estimated)
Sponsor
Royal Marsden NHS Foundation Trust · Other
Who this trial is looking for
This trial is looking for men with melanoma that has spread to lymph nodes. Participants will undergo a special scan to see if it can help with surgery planning.
Are You a Good Fit for This Trial?
Must not be takingAndrogen deprivation therapy
Rules you outProstate cancer
You may be able to join if
I am a man aged 18 or older
I have been diagnosed with metastatic melanoma
I have nodules that can be felt
I have had a FDG PET-CT scan
I am scheduled for surgery to remove the primary tumor
You may not be able to join if
I cannot give written consent to participate
I am not willing to complete all study assessments
I am a woman
I am taking androgen deprivation therapy
I have been diagnosed with prostate cancer
I have had Lu-177 PSMA therapy recently
I am not fluent in English
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Males ≥18 years of age
* Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site
Exclusion Criteria:
* Pati…
Inclusion Criteria:
* Males ≥18 years of age
* Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site
Exclusion Criteria:
* Patients unable to give voluntary written informed consent to participate in this study
* Patients not willing to complete all the study assessments
* Patients who are females
* Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
* Patients who have or have previously been diagnosed with prostate cancer
* Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
* Patients not fluent in English
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
